|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Altogether, our studies reveal a crucial link of EGF receptor to NF-κB activation and tumor progression.
|
27991920 |
2017 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
MET, a receptor tyrosine kinase for hepatocyte growth factor, is associated with tumor progression and acquired resistance to epidermal growth factor tyrosine kinase inhibitors (EGFR-TKI).
|
21733594 |
2012 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Therefore, our findings suggest that AQP3 is required for EGF-EGFR cell signaling in cancer cells and is a therapeutic target for cancer progression.
|
26896765 |
2016 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Epidermal growth factor receptor (EGFR) and Cortactin are molecular markers that are important in tumour progression and development, and interact within the EGF pathway.
|
29201160 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
While elevated expression of HB-EGF in cancer cells and its contribution to tumor progression are well documented, the effects of HB-EGF expression in the tumor stroma have not been clarified.
|
22009535 |
2011 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Consequently, it is not unexpected that EMT has profound impacts on the neoplastic progression, patient survival, as well as the resistance of cancers to therapeutics (taxol, vincristine, oxaliplatin, EGF-R targeted therapy and radiotherapy), independent of the "classical" resistance mechanisms linked to genotoxic drugs.
|
18718806 |
2009 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The EGF family growth factor HB-EGF is synthesized in cancer cells and plays pivotal roles in oncogenic transformation and tumor progression, but the contribution of HB-EGF expressed in tumor stromal cells to tumor growth remains unclear.
|
20190463 |
2010 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that EGF and TPA may share only 1 class of receptors, and that TPA may be used to monitor cancer progression.
|
6118206 |
1981 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Although EGFRvIII is constitutively active and promotes cancer progression, its activity is attenuated compared with EGF-ligated wild-type EGFR, suggesting that EGFRvIII may function together with other signaling receptors in cancer cells to induce an aggressive phenotype.
|
25347738 |
2015 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Aberrant expression or activity of the epidermal growth factor (EGF) receptor family of tyrosine kinases has been associated with tumor progression and an invasive phenotype.
|
9766568 |
1998 |
|
Tumor Progression
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Cripto, the founding member of the EGF-CFC genes, plays an essential role in embryo development and is involved in cancer progression.
|
25629528 |
2015 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Although HB-EGF is widely expressed in tumors when compared with normal tissue, its contribution to cancer progression remains obscure.
|
22209887 |
2012 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Epidermal growth factor receptor (EGFR), a mediator of mitogenic activity of epidermal growth factor and transforming growth factor-alpha, has been shown to be associated with tumour progression.
|
10025878 |
1998 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that proHB-EGF may play an important role in tumor progression.
|
23349913 |
2013 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The over-expression of epidermal growth factor receptor (EGFR) and its ligands, epidermal growth factor (EGF) and transforming growth factor-alpha, is a common feature of epithelial carcinomas and correlates with neoplastic progression.
|
15642791 |
2005 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Epidermal growth factor (EGF) plays a critical role in malignant transformation of hepatocytes and tumor progression.
|
23419149 |
2013 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Supporting biological relevance, increased levels of EGF receptor during tumor progression were correlated with increased expression of the UPR gene signature.
|
26551735 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression.
|
16818638 |
2006 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Growth factors of the epidermal growth factor (EGF)/neuregulin family are involved in tumor progression and, accordingly, antibodies that intercept a cognate receptor, epidermal growth factor receptor (EGFR)/ERBB1, or a co-receptor, HER2, have been approved for cancer therapy.
|
25915843 |
2016 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer.
|
28088463 |
2017 |
|
Tumor Progression
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
As high glucose is able to induce the expression of epidermal growth factor (EGF), which is intimately related with tumor progression, the aim of this study was to evaluate whether curcumin could influence the high glucose-induced EGF/EGFR pathway and the biological activity of pancreatic cancer cells.
|
30542713 |
2019 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Synergistic effect of lung tumor-associated dendritic cell-derived HB-EGF and CXCL5 on cancer progression.
|
24346967 |
2014 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These results suggest that HB-EGF secreted from KRas-mutated colorectal cancer cells promotes IMF migration through ERK and JNK activation, which, in turn, could support cancer progression.
|
28339087 |
2017 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
At later stages of tumor progression, epithelial carcinogenesis is associated with transition to a mesenchymal phenotype, which may contribute to the more aggressive properties of cancer cells and may be stimulated by growth factors such as epidermal growth factor and transforming growth factor-beta.
|
18790770 |
2008 |
|
Tumor Progression
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
The understanding of the significance of EGF-related growth factors in tumor progression provides a framework for a biological approach to the therapy of human gastrointestinal carcinomas.
|
2157713 |
1990 |